UPDATED Jun 29, 2022
What are the best Swedish (OMX) Growth Stocks?
According to our Simply Wall St analysis these are the best Swedish growth companies. We look for companies with high forecasted growth and healthy balance sheets that can deliver sustained growth over the long term.
40 companies meet this criteria in the Swedish market
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: CALTX is expected to become profitable in the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Trading at 98.7% below our estimate of its fair value
Earnings are forecast to grow 60.26% per year
Shareholders have been diluted in the past year
Volatile share price over the past 3 months
Flexion Mobile Plc operates a distribution platform for third party free-to-play games on the Android market worldwide.
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: FLEXM's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Trading at 43.1% below our estimate of its fair value
Earnings are forecast to grow 54.65% per year
Became profitable this year
Does not have a meaningful market cap (SEK788M)
Tempest Security AB (publ) provides security and protection solutions worldwide.
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: TSEC is expected to become profitable in the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Trading at 90.6% below our estimate of its fair value
Earnings are forecast to grow 77.71% per year
Does not have a meaningful market cap (SEK223M)
Shareholders have been diluted in the past year
Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers.
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: MNTC is expected to become profitable in the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Trading at 45.9% below our estimate of its fair value
Earnings are forecast to grow 96.96% per year
Shareholders have been diluted in the past year
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: RVRC's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Trading at 75% below our estimate of its fair value
Earnings are forecast to grow 20.06% per year
Earnings grew by 99% over the past year
High level of non-cash earnings
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally.
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: CAMX is expected to become profitable in the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Trading at 83.2% below our estimate of its fair value
Earnings are forecast to grow 49.97% per year
Earnings have grown 4.8% per year over the past 5 years
No risks detected for CAMX from our risks checks.
Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries.
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: GENO's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Trading at 56.6% below our estimate of its fair value
Earnings are forecast to grow 55.56% per year
Earnings grew by 299.3% over the past year
No risks detected for GENO from our risks checks.
MIPS AB (publ) manufactures and sells helmet-based safety systems in North America, Europe, Sweden, Asia, and Australia.
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: MIPS's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Trading at 37.7% below our estimate of its fair value
Earnings are forecast to grow 26.95% per year
Earnings grew by 81.9% over the past year
High level of non-cash earnings